This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carethers, J. M. Search for Related Content Social Bookmarking                         What's this?

Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor

Division of Gastroenterology UC303, MC 0063 University of California San Diego 9500 Gilman Drive, La Jolla CA 92093-0063, USA, jcarethers{at}ucsd.edu

Colorectal cancer is a prevalent disease in Western countries. While prevention through screening is the best approach to combat the development of colorectal cancer through the removal of precursor adenomas, many patients present with advanced disease that will require surgery and systemic therapy to improve survival. With reference to systemic therapy, the median survival of patients with metastatic colorectal cancer (those with tumor spread to lymph nodes or distant sites) has improved over the past three decades due to the introduction of 5-fluorouracil (5-FU), its subsequent biomodulation, and the addition other chemotherapeutic agents. There is now evidence that the biology of the colorectal tumor, in addition to the stage of colorectal cancer, may predict response to 5-FU-based therapy. More recently, systemic biological therapies that target signaling processes for tumor growth, such as epidermal growth factor receptor, and vascular endothelial growth factor, are also effective in improving patient survival with metastatic colorectal cancer. The use of a combination of systemic therapies that include chemotherapy and biologic therapy should continue to increase patient survival with metastatic colorectal cancer through appropriately designed clinical trials. Treatments based on the biology of the colorectal tumor also need to be examined through clinical trials.

Key Words: colorectal cancer • chemotherapy • biologic therapy • bevacizumab • cetuximab • 5-fluorouracil • epidermal growth factor receptor • tyrosine kinase inhibitor • vascular endothelial growth factor

Therapeutic Advances in Gastroenterology, Vol. 1, No. 1, 33-42 (2008)
DOI: 10.1177/1756283X08093607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?